Metabolic response assessment with 18F-FDG PET/CT: inter-method comparison and prognostic significance for patients with non-small cell lung cancer
Tóm tắt
This study aimed to (1) compare the agreement of two evaluation methods of metabolic response in patients with non-small cell lung cancer (NSCLC) and determine their prognostic value and (2) explore an optimal cutoff of metabolic reduction to distinguish a more favorable subset of responders.
This is a secondary analysis of prospective studies. Enrolled patients underwent 18F-PET/CT within 2 weeks before, during, and months after radiotherapy (post-RT). Metabolic response was assessed using both Peter MacCallum (PM) method of qualitative visual assessment and University of Michigan (UM) method of semiquantitative measurement. The agreement between two methods determined response, and their prediction of outcome was analyzed.
Forty-four patients with median follow-up of 25.2 months were analyzed. A moderate agreement was observed between PM- and UM-based response assessment (Kappa coefficient = 0.434), unveiling a significant difference in CMR rate (
There was a modest discrepancy in metabolic response rates between PM and UM criteria, though both could offer predictive classification for survival. The percentage decrease provides an ordinal value that correlates with prolonged survival, recommending 75 % as the optimal threshold at identifying better responders.
Từ khóa
Tài liệu tham khảo
Ichiya Y, Kuwabara Y, Sasaki M, Yoshida T, Omagari J, Akashi Y, Kawashima A, Fukumura T, Masuda K (1996) A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma. Ann Nucl Med 10:193–200
Hicks RJ, Kalff V, MacManus MP, Ware RE, McKenzie AF, Matthews JP, Ball DL (2001) The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J Nucl Med 42:1605–1613
Kalff V, Hicks RJ, MacManus MP, Binns DS, McKenzie AF, Ware RE, Hogg A, Ball DL (2001) Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol 19:111–118
Mac Manus MP, Hicks RJ, Ball DL, Kalff V, Matthews JP, Salminen E, Khaw P, Wirth A, Rischin D, McKenzie A (2001) F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer 92:886–895
Mac Manus MP, Hicks RJ, Matthews JP, McKenzie A, Rischin D, Salminen EK, Ball DL (2003) Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 21:1285–1292
Weber WA, Petersen V, Schmidt B, Tyndale-Hines L, Link T, Peschel C, Schwaiger M (2003) Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 21:2651–2657
Vansteenkiste J, Fischer BM, Dooms C, Mortensen J (2004) Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol 5:531–540
Pöttgen C, Levegrün S, Theegarten D, Marnitz S, Grehl S, Pink R, Eberhardt W, Stamatis G, Gauler T, Antoch G, Bockisch A, Stuschke M (2006) Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 12:97–106
Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Budach W, Dittmann H, Langen HJ, Bares R (2007) Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer. Lung Cancer 55:165–171
Kong F, Frey K, Quint L, Ten Haken R, Hayman J, Kessler M, Chetty I, Normolle D, Eisbruch A, Lawrence T (2007) A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. J Clin Oncol 25:3116–3123
de Geus-Oei LF, van der Heijden HF, Visser EP, Hermsen R, van Hoorn BA, Timmer-Bonte JN, Willemsen AT, Pruim J, Corstens FH, Krabbe PF, Oyen WJ (2007) Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer. J Nucl Med 48:1592–1598
Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, Castaigne C, Scherpereel A, Mascaux C, Moreau M, Roelandts M, Alard S, Meert AP, Patz EF, Lafitte JJ, Sculier JP, E. L. C. W. P. f. t. I. L. C. S. Project (2008) Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 3:6–12
Xu X, Yu J, Sun X, Yang G, Li K, Fu Z, Han A, Zheng J (2008) The prognostic value of 18F-fluorodeoxyglucose uptake by using serial positron emission tomography and computed tomography in patients with stage III nonsmall cell lung cancer. Am J Clin Oncol 31:470–475
Allen-Auerbach M, Weber WA (2009) Measuring response with FDG-PET: methodological aspects. Oncologist 14:369–377
van Loon J, Grutters J, Wanders R, Boersma L, Oellers M, Dingemans AM, Bootsma G, Geraedts W, Pitz C, Simons J, Fatah SA, Snoep G, Hochstenbag M, Lambin P, De Ruysscher D (2009) Follow-up with 18FDG-PET-CT after radical radiotherapy with or without chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung cancer patients: a prospective study. Eur J Cancer 45:588–595
Harry VN, Semple SI, Parkin DE, Gilbert FJ (2010) Use of new imaging techniques to predict tumour response to therapy. Lancet Oncol 11:92–102
Lee HY, Lee HJ, Kim YT, Kang CH, Jang BG, Chung DH, Goo JM, Park CM, Lee CH, Kang KW (2010) Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer. J Thorac Oncol 5:497–503
Obrzut S, Bykowski J, Badran K, Hayeri MR, Hoh CK (2010) Utility of fluorodeoxyglucose-positron emission tomography in the identification of new lesions in lung cancer patients for the assessment of therapy response. Nucl Med Commun 31:1008–1015
Segall GM (2010) Therapy response evaluation with positron emission tomography-computed tomography. Semin Ultrasound CT MR 31:490–495
Shiraishi K, Nomori H, Ohba Y, Kaji M, Mori T, Shibata H, Oya N, Sasaki J (2010) Repeat FDG-PET for predicting pathological tumor response and prognosis after neoadjuvant treatment in nonsmall cell lung cancer: comparison with computed tomography. Ann Thorac Cardiovasc Surg 16:394–400
Afaq A, Akin O (2011) Imaging assessment of tumor response: past, present and future. Future Oncol 7:669–677
Zander T, Scheffler M, Nogova L, Kobe C, Engel-Riedel W, Hellmich M, Papachristou I, Toepelt K, Draube A, Heukamp L, Buettner R, Ko YD, Ullrich RT, Smit E, Boellaard R, Lammertsma AA, Hallek M, Jacobs AH, Schlesinger A, Schulte K, Querings S, Stoelben E, Neumaier B, Thomas RK, Dietlein M, Wolf J (2011) Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol 29:1701–1708
Yoon DH, Baek S, Choi CM, Lee DH, Suh C, Ryu JS, Moon DH, Lee JS, Kim SW (2011) FDG-PET as a potential tool for selecting patients with advanced non-small cell lung cancer who may be spared maintenance therapy after first-line chemotherapy. Clin Cancer Res 17:5093–5100
Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S–150S
Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M (1999) Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 40:1771–1777
Paquet N, Albert A, Foidart J, Hustinx R (2004) Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues. J Nucl Med 45:784–788
Kuo WH, Wu YC, Wu CY, Ho KC, Chiu PH, Wang CW, Chang CJ, Yu CT, Yen TC, Lin C (2012) Node/aorta and node/liver SUV ratios from (18)F-FDG PET/CT may improve the detection of occult mediastinal lymph node metastases in patients with non-small cell lung carcinoma. Acad Radiol 19:685–692
Skougaard K, Nielsen D, Jensen BV, Hendel HW (2013) Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab. J Nucl Med 54:1026–1031
Ziai D, Wagner T, El Badaoui A, Hitzel A, Woillard JB, Melloni B, Monteil J (2013) Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria. Cancer Imaging 13:73–80
Machtay M, Duan F, Siegel BA, Snyder BS, Gorelick JJ, Reddin JS, Munden R, Johnson DW, Wilf LH, DeNittis A, Sherwin N, Cho KH, Kim SK, Videtic G, Neumann DR, Komaki R, Macapinlac H, Bradley JD, Alavi A (2013) Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial. J Clin Oncol 31:3823–3830